Issue 35, 2019

Modular design of nanobody–drug conjugates for targeted-delivery of platinum anticancer drugs with an MRI contrast agent

Abstract

A multifunctional nanobody–drug conjugate (NDC) was constructed in this work for the targeted delivery of a platinum prodrug and an MRI contrast agent. The NDC can be specifically internalized into EGFR positive cancer cells, resulting in higher therapeutic effect and lower side-effects relative to cisplatin. The Gd-binding domain enables the in situ detection of the drug distribution in vivo.

Graphical abstract: Modular design of nanobody–drug conjugates for targeted-delivery of platinum anticancer drugs with an MRI contrast agent

Supplementary files

Article information

Article type
Communication
Submitted
18 Feb 2019
Accepted
05 Apr 2019
First published
05 Apr 2019

Chem. Commun., 2019,55, 5175-5178

Modular design of nanobody–drug conjugates for targeted-delivery of platinum anticancer drugs with an MRI contrast agent

H. Huang, T. Wu, H. Shi, Y. Wu, H. Yang, K. Zhong, Y. Wang and Y. Liu, Chem. Commun., 2019, 55, 5175 DOI: 10.1039/C9CC01391A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements